Furthermore, the therapeutic potential of FcRn inhibitors was also proven in a mouse model of MuSK+ MG, as confirmation that this category of drugs leads to a reduction in the levels of all IgG subclasses, including IgG4 (Liu et al., 2007b). This evidence concerns the gene MUSK and myasthenia gravis.